Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent or Refractory”

2,659 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 2,659 results

Testing effectiveness (Phase 2)Study completedNCT03625323
What this trial is testing

Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC

Who this might be right for
NSCLCHNSCC
Immutep S.A.S. 187
Testing effectiveness (Phase 2)UnknownNCT03245905
What this trial is testing

Study of Chidamide as a Single-agent Treatment for Patients With Relapse or Refractory B-NHL

Who this might be right for
Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)
Sun Yat-sen University 100
Testing effectiveness (Phase 2)Study completedNCT02312622
What this trial is testing

Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer

Who this might be right for
Stage IV Non-small Cell Lung Cancer (NSCLC)Recurrent Non-small Cell Lung Cancer (NSCLC)Extensive-stage Small Cell Lung Cancer (SCLC)+3 more
Joel Neal 27
Testing effectiveness (Phase 2)Study completedNCT00576979
What this trial is testing

Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

Who this might be right for
Leukemia
City of Hope Medical Center 51
Testing effectiveness (Phase 2)Study completedNCT00003670
What this trial is testing

Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Metastatic Refractory Ovarian Cancer or Primary Peritoneal Cancer

Who this might be right for
Ovarian CancerPrimary Peritoneal Cavity Cancer
Eli Lilly and Company
Testing effectiveness (Phase 2)Study completedNCT00967369
What this trial is testing

Combination Chemotherapy With or Without Bortezomib in Treating Patients With Classical Hodgkin Lymphoma That Has Returned or Does Not Respond to Prior Treatment.

Who this might be right for
Recurrent Classic Hodgkin LymphomaRefractory Classic Hodgkin Lymphoma
M.D. Anderson Cancer Center 20
Testing effectiveness (Phase 2)UnknownNCT02060656
What this trial is testing

Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND)

Who this might be right for
Diffuse Large B-Cell Lymphoma
Royal Marsden NHS Foundation Trust 92
Testing effectiveness (Phase 2)Ended earlyNCT06912529
What this trial is testing

Axicabtagene Ciloleucel CAR T-cells in Patients With Relapsed or Refractory Primary Mediastinal B-cell Lymphoma

Who this might be right for
B-cell Lymphoma RefractoryB-cell Lymphoma Recurrent
Universität Münster 1
Early research (Phase 1)Active Not RecruitingNCT03233854
What this trial is testing

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies

Who this might be right for
B Acute Lymphoblastic LeukemiaCD19 PositiveMinimal Residual Disease+1 more
Stanford University 56
Large-scale testing (Phase 3)Ended earlyNCT02298166
What this trial is testing

Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutations

Who this might be right for
Acute Myeloid Leukemia
University of Ulm 9
Testing effectiveness (Phase 2)Study completedNCT00553202
What this trial is testing

Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia

Who this might be right for
Leukemia
Children's Oncology Group 158
Early research (Phase 1)Study completedNCT02568553
What this trial is testing

Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma

Who this might be right for
Recurrent Burkitt LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Grade 1 Follicular Lymphoma+23 more
National Cancer Institute (NCI) 35
Early research (Phase 1)Study completedNCT00016237
What this trial is testing

Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment

Who this might be right for
Bladder CancerKidney CancerLung Cancer
EMD Serono
Testing effectiveness (Phase 2)Ended earlyNCT02420795
What this trial is testing

Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
Central Nervous System LymphomaGastric Mantle Cell LymphomaRecurrent Mantle Cell Lymphoma+4 more
M.D. Anderson Cancer Center 16
Testing effectiveness (Phase 2)Study completedNCT00003737
What this trial is testing

Rebeccamycin Analog in Treating Children With Relapsed or Refractory Neuroblastoma

Who this might be right for
Neuroblastoma
Memorial Sloan Kettering Cancer Center 30
Early research (Phase 1)Active Not RecruitingNCT05784441
What this trial is testing

JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)

Who this might be right for
Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Janssen Research & Development, LLC 21
Testing effectiveness (Phase 2)Study completedNCT01244451
What this trial is testing

GIMEMA CLL0809 Study (BendOfa)

Who this might be right for
Patients With CLL Relapsing After an Initial Response (CR, PR ≥ 6 Months) Following no More Than Two Prior Treatment Lines; orPatients With CLL Refractory (SD, PD or CR/PR < 6 Months) Following no More Than Two Prior Treatment Lines
Gruppo Italiano Malattie EMatologiche dell'Adulto 49
Early research (Phase 1)Study completedNCT01246622
What this trial is testing

Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)+4 more
Roswell Park Cancer Institute 32
Testing effectiveness (Phase 2)UnknownNCT05137886
What this trial is testing

PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma

Who this might be right for
Hodgkin Lymphoma, AdultRelapseRefractory Hodgkin Lymphoma
Institute of Hematology & Blood Diseases Hospital, China 47
Testing effectiveness (Phase 2)Study completedNCT02600897
What this trial is testing

Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Who this might be right for
Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche 114
Next Page